Aldevron has expanded its leadership team by appointing Michelle Berg President of its GMP nucleic acids business unit. She will report to Michael Chambers, Aldevron’s founder and CEO.
In this senior leadership role, Berg will oversee Aldevron’s strategy to provide GMP plasmids and mRNA for gene editing, gene therapy, and cell therapy applications. She will work closely with the Company’s operational team to meet the requirements of these growing fields, while supporting the clinical and commercial efforts of Aldevron’s clients. Aldevron’s GMP plasmid facility, located in Fargo, N.D., is the largest in the world.
“Michelle was one of our original hires. She helped to build Aldevron and is the ideal leader for the GMP business unit” said Chambers. “Michelle brings an impressive mix of patient advocacy, gene therapy experience, and a deep knowledge of Aldevron and our culture.”
Berg joins Aldevron with over 20 years of experience and leadership in the biotechnology sector. Most recently, she served as Vice President of Patient Affairs and Community Engagement for Abeona Therapeutics, a company focused on developing novel gene and cell therapy approaches for treatment of people affected by rare diseases including Epidermolysis Bullosa, Sanfilippo syndrome, and Batten disease. Prior to that, Berg held a variety of roles with increasing reach and responsibility at Aldevron for 16 years, seeing it through several pivotal growth and expansion cycles.
“I’m exceedingly proud of the company that Aldevron has become and the significant contributions made to numerous sectors through high quality deliverables and relationship-driven focus that remain core to our values,” said Berg. “It’s an honor to return in this newly created capacity to lead the service of these transformational fields and ultimately accelerate success for those who are awaiting it most – the patients.”
Berg earned a Bachelor of Science in Biotechnology from North Dakota State University (NDSU), Fargo, which will open Aldevron Tower on campus Q1 of 2020. She is a contributing author and speaker on patient-focused programming, rare disease advocacy, and accessible education on genetic medicines. In addition to her roles with Abeona and Aldevron, she has performed research on behalf of the Department of Plant Sciences at NDSU.